top of page
Aro-Biotherapeutics-About-Us-Banner-2.jp
Dark%20blue%20gradeint%20overlay_edited.

Scientific Publications & Presenations

2024 WORLD Symposium

This symposium is designed to help researchers and clinicians to better manage and understand diagnostic options for patients with lysosomal diseases, identify areas requiring additional basic and clinical research, public policy and regulatory attention, and identify the latest findings in the natural history of lysosomal diseases.

POSTER: Nonclinical Studies in Non-Human Primates on ABX-1100:

A Centyrin:Gys1 siRNA Conjugate for the Treatment of Pompe

siRNA-targeting-and-delivery-platform-inhibits-glycogen-synthesis.jpg

POSTER: A novel Centyrin:siRNA targeting and delivery platform inhibits glycogen synthesis and reduces glycogen levels in skeletal and cardiac muscle in a mouse model of Pompe disease

Presentation siRNA-targeting-and-delivery-platform-inhibits-glycogen-synthesis.jpg

PRESENTATION: A novel Centyrin:siRNA targeting and delivery platform inhibits glycogen synthesis and reduces glycogen levels in skeletal and cardiac muscle in a mouse model of Pompe disease

POSTER Centyrin-targeted glycogen synthase-1 siRNA conjugates- A novel muscle targeted gly

POSTER: Centyrin-targeted glycogen synthase-1 siRNA conjugates: A novel, muscle targeted glycogen reduction therapy for the treatment of Pompe Disease

PRESENTATION Centyrin-targeted glycogen synthase-1 siRNA conjugates- A novel muscle target

PRESENTATION: Centyrin-targeted glycogen synthase-1 siRNA conjugates: A novel, muscle targeted glycogen reduction therapy for the treatment of Pompe Disease

2022 TIDES USA Conference

Centyrin-targeted siRNA conjugates demonstrate potential new therapeutic approach for reduction of skeletal muscle glycogen in Pompe disease

Authors: Aro Biotherapeutics

2022 ELRIG Conference

Creating A New Class of Centyrin - Oligonucleotide Therapeutics

Authors: Aro Biotherapeutics

2022 3rd RNAi-Based Therapeutics Summit

Creating a New Class of Receptor Targeted Genetic Medicines

Authors: Aro Biotherapeutics

2022 Muscular Dystrophy Association Conference Poster

Extra-hepatic delivery of Centyrin-targeted oligonucleotides

Authors: Rebecca Meyer

2021 Oligonucleotides Therapeutics Society Meeting

Creating a New Class of Receptor Targeted Genetic Medicines

Authors: Aro Biotherapeutics

2021 Molecular Therapy Publication

Centyrin ligands for extrahepatic delivery of siRNA

Authors: Donna Klein, Shalom Goldberg, Christopher S. Theile, Richard Dambra, Kathleen Haskell, Elise Kuhar, Tricia Lin, Rubina Parmar, Muthiah Manoharan, Mark Richter, Meizhen Wu, Jeannine Mendrola Zarazowski, Vasant Jadhav, Martin A. Maier, Laura Sepp-Lorenzino, Karyn O’Neil, and Vadim Dudkin

2020 RAS Europe Poster Presentation

Bispecific Centyrin – panKRAS siRNA conjugate with anti-proliferative activity in KRAS mutant tumor cell lines

Authors: Robert Kolakowski, Russell C. Addis, Swapnil Kulkarni, Joshua Gorsky, Rebecca Meyer, Yao Xin, Evana Mortezavi, Evan Greenawalt, Karyn T. O’Neil, Steven G. Nadler

2020 AACR Poster Presentation

Tumor-targeted knockdown of KRAS mutants with novel Centyrin: siRNA conjugates

Authors: Robert Kolakowski, Russell C. Addis, Swapnil Kulkarni, Joshua Gorsky, Rebecca Meyer, Yao Xin, Evana Mortezavi, Evan Greenawalt, Karyn T. O’Neil, Steven G. Nadler

2020 Oligonucleotide Society 2020 meeting

Tumor Targeted Knockdown of KRAS mutants with novel Centyrin: siRNA conjugates

Authors: Robert Kolakowski, Russell C. Addis, Swapnil Kulkarni, Joshua Gorsky, Rebecca Meyer, Yao Xin, Evana Mortezavi, Evan Greenawalt, Karyn T. O’Neil, Steven G. Nadler

2019 AACR Poster Presentation

ABX9xx: A multi-specific Centyrin that synergizes to attenuate intracellular signaling in cMET/EGFR positive tumor cells

Authors: Russ Addis, Robert Kolakowski, Swapnil Kulkarni, Josh Gorsky, Rebecca Meyer, Yao Xin, Steve Nadler, Karyn O’Neil

2017 Bioconjugate Chemistry

Evaluation of a Centyrin-Based Near-Infrared Probe for Fluorescence-Guided Surgery of Epidermal Growth Factor Receptor Positive Tumors

Authors: Sakkarapalayam M. Mahalingam, Vadim Y. Dudkin, Shalom Goldberg, Donna Klein, Fang Yi, Sunil Singhal, Karyn T. O’Neil and Philip S. Low

2016 Protein Engineering, Design & Selection

Engineering a targeted delivery platform using Centyrins

Authors: Shalom D. Goldberg, Rosa M.F. Cardoso, Tricia Lin, Tracy Spinka-Doms, Donna Klein, Steven A. Jacobs, Vadim Dudkin, Gary Gilliland and Karyn T. O’Neil

2014 Protein Engineering, Design & Selection

Selection of high-affinity Centyrin FN3 domains from a simple library diversified at a combination of strand and loop position

Authors: Michael D. Diem, Linus Hyun, Fang Yi, Randi Hippensteel, Elise Kuhar, Cassandra Lowenstein, Edward J. Swift, Karyn T. O’Neil and Steven A. Jacobs

2012 Protein Engineering, Design & Selection

Design of novel FN3 domains with high stability by a consensus sequence approach

Authors: Steven A.Jacobs, Michael D. Diem, Jinquan Luo, Alexey Teplyakov, Galina Obmolova, Thomas Malia, Gary L. Gilliland and Karyn T. O’Neil

bottom of page